Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

By M. Piccart-Gebhart, M. Procter, B. Leyland-Jones, A. Goldhirsch, M. Untch, I. Smith, L. Gianni, J. Baselga, R. Bell, C. Jackisch and 22 more. New England Journal of Medicine, 2005

5,148 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/77bd23d51a39fc62f4e3f947acd3cdd2df0a1b43

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. D. Duda
2. Rakesh K. Jain
3. Jay S. Loeffler
4. Aleix Prat
5. Jeffrey W. Clark
6. Dihua Yu
7. Charles M. Perou
8. Carlos L. Arteaga

In Oncology

1. Rakesh K. Jain
2. J. Baselga
3. Carlos L. Arteaga
4. R. Nahta
5. Andrew K. Joe
6. D. Duda
7. Jordi Bruix1 , 2
8. Jay S. Loeffler

In Radiology, Nuclear Medicine and Imaging

1. Carlos L. Arteaga
2. J. Baselga
3. R. Nahta
4. Jordi Bruix1 , 2
5. J. Engelman
6. M. Sliwkowski
7. J. Herrmann
8. N. Iqbal

Citations in the corpus

• Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. (2010, background): “Trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2), significantly improves survival in patients with HER2-positive breast cancer in both the metastatic(1-3) and adjuvant settings.(4-9) However, despite this notable success, there is still a need to improve H”
• Deconstructing the molecular portraits of breast cancer (2010, background): “…HER2 overexpression and/or amplification (HER2þ) confers increased resistance to endocrine treatment in preclinical models (Benz et al., 1992; Pietras et al., 1995) and in ER-positive breast cancer patients treated with tamoxifen (Houston et al., 1999; Lipton et al., 2003) or AIs (Lipton et…”
• Treatment of HER2-positive breast cancer: current status and future perspectives (2012, background): “Of note, the statistically significant advantage in overall survival initially observed with the addition of trastuzumab to chemotherapy in the HERA tria”
• Tumor metastasis: mechanistic insights and clinical challenges (2006, background): “, and successful data in the adjuvant (lymph node–positive) setting have been reporte”
• Mechanisms and insights into drug resistance in cancer (2013, background): “…(EGFR) tyrosine kinase domain in non-small cell lung carcinoma (Lynch et al., 2004; Shepherd et al., 2005; Taron et al., 2005), and (iii) trastuzumab targeting human epidermal growth factor receptor-2 (HER-2) receptor in breast carcinomas (Slamon et al., 2001; Piccart-Gebhart et al., 2005).”